Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study

BACKGROUND: Metastatic adenoid cystic carcinoma (ACC) is a malignant tumor lacking effective therapies. We evaluated a multitargeted tyrosine kinase inhibitor anlotinib in patients with metastatic ACC. METHODS: From September 2018 to October 2020, nineteen patients with histologically confirmed meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Ning, Fang, Yu, Wang, Jinni, Tian, Xiaopeng, Ma, Shuyun, Cai, Jun, Zhang, Yuchen, Xia, Yi, Liu, Panpan, Cai, Qingqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459595/
https://www.ncbi.nlm.nih.gov/pubmed/36093515
http://dx.doi.org/10.21037/tcr-21-2433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459595/
https://www.ncbi.nlm.nih.gov/pubmed/36093515
http://dx.doi.org/10.21037/tcr-21-2433

Ejemplares similares